BIOMAT Database Logo BIOMAT Database Logo

[Evolution of techniques for preparation of labile blood products (LBP): pathogen inactivation in LBP]. 2009

C Naegelen, and H Isola, and D Dernis, and J-P Maurel, and R Tardivel, and S Bois, and C Vignoli, and J-P Cazenave
EFS Bourgogne-Franche-Comté, 25000 Besançon, France. christian.naegelen@efs.sante.fr

The techniques for inactivation of pathogens in labile blood products (LBP) would appear to be the new strategy which will permit us to increase transfusion safety in the face of the risks of transmission of pathogenic agents by LBP. Various methods are in the course of development or already validated and used in France. The latter only apply however to plasma or platelet concentrates. The mechanisms of action and the efficacy of inactivation and attenuation of pathogenic agents vary with the different techniques. Each of these constitutes a preparative procedure composed of unit steps which have to be fully mastered in order to ensure the quality and transfusion efficacy of the treated product.

UI MeSH Term Description Entries
D008751 Methylene Blue A compound consisting of dark green crystals or crystalline powder, having a bronze-like luster. Solutions in water or alcohol have a deep blue color. Methylene blue is used as a bacteriologic stain and as an indicator. It inhibits GUANYLATE CYCLASE, and has been used to treat cyanide poisoning and to lower levels of METHEMOGLOBIN. Methylthionine Chloride,Swiss Blue,Basic Blue 9,Chromosmon,Methylene Blue N,Methylthioninium Chloride,Urolene Blue,Blue 9, Basic,Blue N, Methylene,Blue, Methylene,Blue, Swiss,Blue, Urolene
D010949 Plasma The residual portion of BLOOD that is left after removal of BLOOD CELLS by CENTRIFUGATION without prior BLOOD COAGULATION. Blood Plasma,Fresh Frozen Plasma,Blood Plasmas,Fresh Frozen Plasmas,Frozen Plasma, Fresh,Frozen Plasmas, Fresh,Plasma, Blood,Plasma, Fresh Frozen,Plasmas,Plasmas, Blood,Plasmas, Fresh Frozen
D011786 Quality Control A system for verifying and maintaining a desired level of quality in a product or process by careful planning, use of proper equipment, continued inspection, and corrective action as required. (Random House Unabridged Dictionary, 2d ed) Control, Quality,Controls, Quality,Quality Controls
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D001793 Blood Preservation The process by which blood or its components are kept viable outside of the organism from which they are derived (i.e., kept from decay by means of a chemical agent, cooling, or a fluid substitute that mimics the natural state within the organism). Blood Preservations,Preservation, Blood,Preservations, Blood
D001803 Blood Transfusion The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed) Blood Transfusions,Transfusion, Blood,Transfusions, Blood
D006358 Hot Temperature Presence of warmth or heat or a temperature notably higher than an accustomed norm. Heat,Hot Temperatures,Temperature, Hot,Temperatures, Hot
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000094902 Blood Banking The administrative procedures and methods required for collecting, characterizing and storing blood or plasma in BLOOD BANKS. Banking, Blood
D012449 Safety Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property. Safeties

Related Publications

C Naegelen, and H Isola, and D Dernis, and J-P Maurel, and R Tardivel, and S Bois, and C Vignoli, and J-P Cazenave
Pathogen inactivation of labile blood products.
June 2001, Transfusion medicine (Oxford, England),
C Naegelen, and H Isola, and D Dernis, and J-P Maurel, and R Tardivel, and S Bois, and C Vignoli, and J-P Cazenave
[Pathogen inactivation in labile blood products: transfusion safety and economic impact].
January 2006, Bulletin de l'Academie nationale de medecine,
C Naegelen, and H Isola, and D Dernis, and J-P Maurel, and R Tardivel, and S Bois, and C Vignoli, and J-P Cazenave
[Techniques of preparation and indications of labile blood products].
April 2011, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine,
C Naegelen, and H Isola, and D Dernis, and J-P Maurel, and R Tardivel, and S Bois, and C Vignoli, and J-P Cazenave
Pathogen inactivation of labile blood components.
June 2001, Transfusion medicine (Oxford, England),
C Naegelen, and H Isola, and D Dernis, and J-P Maurel, and R Tardivel, and S Bois, and C Vignoli, and J-P Cazenave
Pathogen inactivation in blood products.
January 2002, Current medicinal chemistry,
C Naegelen, and H Isola, and D Dernis, and J-P Maurel, and R Tardivel, and S Bois, and C Vignoli, and J-P Cazenave
Phenothiazinium derivatives for pathogen inactivation in blood products.
January 2007, Journal of photochemistry and photobiology. B, Biology,
C Naegelen, and H Isola, and D Dernis, and J-P Maurel, and R Tardivel, and S Bois, and C Vignoli, and J-P Cazenave
[Labile blood products and their preparation].
June 2001, La Revue du praticien,
C Naegelen, and H Isola, and D Dernis, and J-P Maurel, and R Tardivel, and S Bois, and C Vignoli, and J-P Cazenave
[Universal implementation of pathogen inactivation in labile blood products is a major step towards transfusion safety].
December 2010, Bulletin de l'Academie nationale de medecine,
C Naegelen, and H Isola, and D Dernis, and J-P Maurel, and R Tardivel, and S Bois, and C Vignoli, and J-P Cazenave
[Mode of preparation of labile blood products--available products].
January 1999, Presse medicale (Paris, France : 1983),
C Naegelen, and H Isola, and D Dernis, and J-P Maurel, and R Tardivel, and S Bois, and C Vignoli, and J-P Cazenave
French evaluation of conditions for the systematic implementation of leucocyte removal in labile blood products (LBP).
December 1998, Transfusion science,
Copied contents to your clipboard!